Cansortium Ownership

CNTMF Stock  USD 0.08  0  2.35%   
Cansortium holds a total of 225.38 Million outstanding shares. Cansortium retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in otc stocks such as Cansortium in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cansortium, and when they decide to sell, the otc stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansortium. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population.

Cansortium OTC Stock Ownership Analysis

About 21.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.96. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cansortium recorded a loss per share of 0.1. The entity had not issued any dividends in recent years. Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. Cansortium Inc. was incorporated in 2018 and is headquartered in Miami, Florida. Cansortium operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.The quote for Cansortium is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Cansortium please contact Robert Beasley at 305 902 2720 or go to https://www.getfluent.com.

Cansortium Outstanding Bonds

Cansortium issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cansortium uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cansortium bonds can be classified according to their maturity, which is the date when Cansortium has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Currently Active Assets on Macroaxis

Other Information on Investing in Cansortium OTC Stock

Cansortium financial ratios help investors to determine whether Cansortium OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cansortium with respect to the benefits of owning Cansortium security.